Weed (BUDZ) Change in Accured Expenses (2010 - 2026)
Weed's (BUDZ) quarterly Change in Accured Expenses came in at $73412.0 in Q1 2026, up 65.13% year-on-year from $44456.0 in Q1 2025, and up 27.64% quarter-over-quarter from $57514.0 in Q4 2025.
Weed (BUDZ) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Weed's Change in Accured Expenses history runs 13 years deep, the most recent figure standing at $73412.0 for Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 65.13% year-over-year to $73412.0 in Q1 2026; TTM through Mar 2026 was $238919.0, a 16.51% decrease from a year earlier, with the FY2025 full-year figure at $209963.0, up 374.78% from the prior year.
- Change in Accured Expenses improved to $73412.0 in Q1 2026 per BUDZ's latest filing, from $57514.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $167635.0 in Q2 2024 and bottomed at -$206812.0 in Q3 2023.
- The 5-year median for Change in Accured Expenses is $26394.0 (2024), against an average of $11208.2.
- Biggest YoY gain for Change in Accured Expenses was 800.68% in 2024; the steepest drop was 2029.99% in 2024.
- Year by year, Change in Accured Expenses stood at $7789.0 in 2022, then tumbled by 429.61% to -$25673.0 in 2023, then soared by 202.81% to $26394.0 in 2024, then soared by 117.91% to $57514.0 in 2025, then climbed by 27.64% to $73412.0 in 2026.
- Per Business Quant, the three latest BUDZ Change in Accured Expenses figures stand at $73412.0 (Q1 2026), $57514.0 (Q4 2025), and $54026.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.19 Bn | 87.33 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.52 Bn | 30.58 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.22 Bn | 21.07 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.29 Bn | 18.48 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.59 Bn | 12.16 Bn | 785.00 Mn | - |
| 10 | Weed | 2.77 Mn | 2.77 Mn | - | 73,412.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73,412.00 |
| Mar 31, 2026 | 73,412.00 |
| Dec 31, 2025 | 57,514.00 |
| Dec 31, 2025 | 57,514.00 |
| Sep 30, 2025 | 54,026.00 |
| Sep 30, 2025 | 54,026.00 |
| Jun 30, 2025 | 53,967.00 |
| Jun 30, 2025 | 53,967.00 |
| Mar 31, 2025 | 44,456.00 |
| Mar 31, 2025 | 44,456.00 |
| Dec 31, 2024 | 26,394.00 |
| Dec 31, 2024 | 26,394.00 |
| Sep 30, 2024 | 47,665.00 |
| Sep 30, 2024 | 47,665.00 |
| Jun 30, 2024 | 167,635.00 |
| Jun 30, 2024 | 167,635.00 |
| Mar 31, 2024 | -197,471.00 |
| Mar 31, 2024 | -197,471.00 |
| Dec 31, 2023 | -25,673.00 |
| Dec 31, 2023 | -25,673.00 |